.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The VIVID and VISTA phase 3 trials were among the landmark studies establishing anti-VEGF therapy for center-involving diabetic macular edema. Patients were randomized to aflibercept 2 mg every four weeks, aflibercept every eight weeks after five monthly loading doses, or macular laser. At 100 weeks, both aflibercept regimens produced substantial and sustained visual-acuity gains, while the laser groups gained very little. Benefits extended beyond letter-score improvement, with more patients achieving meaningful vision gains and improvement in diabetic retinopathy severity. The study supports anti-VEGF therapy as a central component of DME management and provides evidence for a less frequent eight-week maintenance strategy after loading in appropriate patients. For HCPs, treatment decisions should still be personalised around baseline vision, OCT anatomy, systemic diabetic control, adherence and treatment burden. The evidence is directly aligned with AIOC's retina track on anti-VEGF regimens for diabetic macular edema.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The VIVID and VISTA phase 3 trials were among the landmark studies establishing anti-VEGF therapy for center-involving diabetic macular edema. Patients were randomized to aflibercept 2 mg every four weeks, aflibercept every eight weeks after five monthly loading doses, or macular laser. At 100 weeks, both aflibercept regimens produced substantial and sustained visual-acuity gains, while the laser groups gained very little. Benefits extended beyond letter-score improvement, with more patients achieving meaningful vision gains and improvement in diabetic retinopathy severity. The study supports anti-VEGF therapy as a central component of DME management and provides evidence for a less frequent eight-week maintenance strategy after loading in appropriate patients. For HCPs, treatment decisions should still be personalised around baseline vision, OCT anatomy, systemic diabetic control, adherence and treatment burden. The evidence is directly aligned with AIOC's retina track on anti-VEGF regimens for diabetic macular edema.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
2 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
3 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
3 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
2 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
3 days back
